- Home
- PHAR vs ULCC Comparison
PHAR vs ULCC Comparison
Compare PHAR & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | ULCC |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHAR | ULCC |
|---|---|---|
| Price | $17.20 | $4.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 10 |
| Target Price | ★ $38.00 | $5.56 |
| AVG Volume (30 Days) | 27.7K | ★ 4.2M |
| Earning Date | 11-06-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $362,274,000.00 | ★ $3,729,000,000.00 |
| Revenue This Year | $25.19 | $0.13 |
| Revenue Next Year | $4.47 | $14.68 |
| P/E Ratio | $2,989.65 | ★ N/A |
| Revenue Growth | ★ 26.78 | 1.77 |
| 52 Week Low | $7.50 | $2.89 |
| 52 Week High | $18.30 | $10.26 |
Technical Indicators
Market Signals| Indicator | PHAR | ULCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 48.98 |
| Support Level | $16.55 | $4.51 |
| Resistance Level | $17.37 | $5.57 |
| Average True Range (ATR) | 0.68 | 0.21 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 41.95 | 25.56 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.